Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Lexicon Pharmaceuticals will present clinical data for sotagliflozin in Type 1 diabetes and pilavapadin in diabetic peripheral neuropathic pain at the ADA 2026 Scientific Sessions in New Orleans. The sotagliflozin data includes a pooled analysis from the inTandem trials, reinforcing the drug's mechanistic benefits and supporting a potential NDA resubmission for T1D currently on track for mid-2026.
Key figures
- Drug Name
- sotagliflozin
- Conference dates
- June 5-8, 2026
- Nda resubmission timeline
- mid-year 2026
- Total patients studied sotagliflozin
- 20000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.